---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-209789"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:24:30.589898+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics Q1 revenue $22.5M, net loss $9.9M; Cullgen acquisition closed; NDA for F351 submitted

## Summary
- Q1 2026 revenue $22.5M (+2% YoY); GAAP basic EPS $(0.10); net loss $9.9M vs $3.7M net income YoY.
- Non-GAAP adjusted net loss $4.2M vs adjusted net income $2.9M in Q1 2025.
- Completed acquisition of Cullgen for ~$300M all-stock, expanding pipeline into inflammatory diseases and cancers.
- NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 with priority review.
- FY 2026 revenue guidance reaffirmed at $100.5-$111.0M; first patient enrolled in Phase 2/3 trial for radiation-induced lung injury.

## SEC filing metadata
- accession: 0001193125-26-209789
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/0001193125-26-209789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/gyre-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-209789
- JSON: https://secwatch.observer/filing/0001193125-26-209789.json
- Plain text: https://secwatch.observer/filing/0001193125-26-209789.txt

## Source-grounded claims
- claim_id: 9a33771756927e2ab9471a2598a3c71796e4e75c
  claim: GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2026 results: revenue $22.5 million, EPS $(0.10). Guidance reaffirmed.
  evidence_excerpt: in such a filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update Q1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1124105/000119312526209789/0001193125-26-209789-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.